A global medical consensus has led to the official renaming of Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS). The change, supported by over 14,000 survey responses and input from 56 organizations worldwide, reflects a shift in understanding a condition that affects an estimated 170 million women globally.
The old name was often misleading. The term “polycystic ovary” suggested the condition was defined by cysts on the ovaries. However, what appears as cysts on some ultrasounds are actually immature follicles, a symptom of hormonal dysfunction rather than the cause. This confusion had real consequences for diagnosis. A 2025 study found that while population-based data show a prevalence of 4 to 19.6 percent, health system records capture only 0.2 to 5.2 percent. Research also shows that Black and African American patients are 69 percent more likely to have a missed diagnosis compared to non-Hispanic White patients.
The new name breaks down into three components. “Polyendocrine” refers to the involvement of multiple hormone systems, including reproductive hormones, androgens, insulin, and neuroendocrine hormones. “Metabolic” highlights insulin resistance as a core feature for many women, carrying significant downstream risks. “Ovarian” acknowledges that ovarian dysfunction, including irregular cycles and fertility challenges, remains part of the picture but is now understood as one piece of a larger puzzle.
The metabolic component is central. A 2025 study describes a bidirectional relationship between insulin resistance and PMOS symptoms such as hyperandrogenism and ovulatory dysfunction. PMOS itself also increases the risk of type 2 diabetes. Evidence shows the condition has reproductive, metabolic, and psychological impacts across a woman’s lifespan.
The terminology change is expected to improve diagnosis. When clinicians heard “PCOS,” they often looked for ovarian cysts and menstrual irregularities. The new name, “polyendocrine metabolic ovarian syndrome,” widens the diagnostic lens. Many women with PMOS do not fit the narrow classic presentation. Some have regular periods. Others present with irregular menstrual cycles but do not have visible follicles on an ultrasound. Symptoms like insulin resistance, elevated androgens, acne, hair changes, or metabolic markers point to the same underlying dysfunction. The hope is that reframing the condition as metabolic and endocrine will prompt earlier and more comprehensive screening.
For women diagnosed with PCOS, the name change validates that the condition is not just about the ovaries. It is a whole-body condition that requires whole-body care, including metabolic screening, cardiovascular risk assessment, and attention to mental health. For those who have suspected something was off but lacked answers, the evolving understanding of PMOS may work in their favor. Experts suggest asking healthcare providers about comprehensive hormone and metabolic testing, not just an ultrasound. Understanding the differences between PMOS and other conditions like endometriosis can also help women advocate for themselves.
